Get the Stockscreener App
30.34
4.75%
-1.45
Upstream Bio Inc stock is traded at $30.34, with a volume of 116.05K.
It is down -4.75% in the last 24 hours and up +3.66% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
See More
Previous Close:
$31.79
Open:
$31.62
24h Volume:
116.05K
Relative Volume:
0.23
Market Cap:
$1.63B
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-23.62
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
-2.32%
1M Performance:
+3.66%
6M Performance:
+162.62%
1Y Performance:
+181.15%
1-Day Range:
$30.13
$31.62
1-Week Range:
$29.08
$32.52
52-Week Range:
$5.14
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
30.23 | 1.72B | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Evercore ISI | Outperform |
| Oct-14-25 | Initiated | Truist | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Upstream Bio Inc Stock (UPB) Latest News
Will Upstream Bio Inc. stock attract ESG investorsBlue Chip Stock Analysis & Get Ahead with Our Profit-Packed Picks - bollywoodhelpline.com
Aug Setups: What is the next catalyst for Upstream Bio IncEarnings Summary Report & Scalable Portfolio Growth Methods - baoquankhu1.vn
Aug Levels: Is CSGS forming bullish engulfing patterns2025 Earnings Impact & Consistent Profit Alerts - baoquankhu1.vn
Sectors Review: Is Upstream Bio Inc a cyclical or defensive stockTake Profit & Community Verified Trade Alerts - baoquankhu1.vn
Why Upstream Bio (UPB) Is Up 12.2% After JPM Debut And VALINAT Hopes - simplywall.st
Can Upstream Bio Inc outperform in the next rallyWeekly Trading Summary & Long-Term Growth Stock Strategies - baoquankhu1.vn
Upstream Bio stock hits all-time high at 33.05 USD By Investing.com - Investing.com Nigeria
Aug Volume: Is Upstream Bio Inc a defensive stockMarket Risk Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
Upstream Bio (NASDAQ:UPB) Reaches New 52-Week HighHere's What Happened - MarketBeat
US Market Recap: Can Upstream Bio Inc ride the EV wave2025 Price Action Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Positioning Upstream Bio for Commercial Success: Buy Rating on UPB Driven by Physician Enthusiasm and Long-Acting TSLP Opportunity Ahead of VALINAT Readout - TipRanks
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Upstream Bio’s Verekitug Study: A Potential Game-Changer for Severe Asthma Treatment - MSN
Fed Watch: Is Upstream Bio Inc stock a bargain at current levelsJuly 2025 Final Week & Weekly Hot Stock Watchlists - Bộ Nội Vụ
Is Upstream Bio Inc. stock vulnerable to regulatory risks2025 Technical Patterns & Weekly Top Gainers Alerts - Улправда
How Upstream Bio Inc. stock reacts to Fed rate cutsMarket Growth Report & Free Community Consensus Stock Picks - Улправда
Will Upstream Bio Inc. stock maintain dividend yield2025 Trading Recap & Weekly Stock Breakout Alerts - Улправда
Is Upstream Bio Inc. stock a bargain at current levelsMarket Performance Summary & Stepwise Swing Trade Plans - Улправда
Upstream Bio: Fully Priced After Recent Rally (NASDAQ:UPB) - Seeking Alpha
How Invesco Quality Municipal Income Trust stock performs after earningsMarket Sentiment Review & Technical Buy Zone Confirmations - Улправда
Is National Vision Holdings Inc. stock positioned for long term growthTrade Exit Summary & Daily Price Action Insights - Улправда
Upstream Bio (NASDAQ:UPB) Trading 7.8% HigherTime to Buy? - MarketBeat
Will Upstream Bio Inc. stock rally after Fed decisionsTrading Volume Surges & Free High Yield Market Plays - Улправда
Upstream Bio initiated with an Outperform at LifeSci Capital - MSN
Upstream Bio (NASDAQ:UPB) Stock Price Down 6.2%What's Next? - MarketBeat
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Upstream Bio Inc Stock Price ($UPB), Quote & News - eToro
Upstream Bio initiated with an outperform at Mizuho - MSN
AI Indicators Detect Buy Opportunity in Zenith Drugs LimitedCash Flow Trends & Outstanding Investment Returns - earlytimes.in
Geopolitics Watch: How Upstream Bio Inc stock reacts to Fed rate cutsWeekly Market Report & Fast Momentum Entry Tips - moha.gov.vn
Upstream Bio (NASDAQ:UPB) Shares Down 3.4%Time to Sell? - MarketBeat
Treasury Yields: How Upstream Bio Inc stock reacts to global recession fearsBuy Signal & Reliable Breakout Forecasts - moha.gov.vn
Upstream Bio Reports Progress in Respiratory Trials - MSN
Upstream Bio (NASDAQ:UPB) Stock Price Up 4.8%Should You Buy? - MarketBeat
Upstream Bio (UPB) price target decreased by 18.03% to 51.00 - MSN
Upstream Bio (UPB): NASDAQ Biotech Index Entry Sparks the Big Rerating Debate - parameter.io
Upstream Bio, Inc.(NasdaqGS: UPB) added to NASDAQ Biotechnology Index - marketscreener.com
Upstream Bio, Inc. (UPB) Eps Diluted (Quarterly) - Zacks Investment Research
Upstream Bio, Inc. (NASDAQ:UPB) Receives $45.25 Average Price Target from Brokerages - Defense World
Can Upstream Bio Inc. stock weather global recessionPortfolio Risk Report & Accurate Entry and Exit Point Alerts - Улправда
Why retail investors favor Upstream Bio Inc. stockWeekly Risk Summary & Low Volatility Stock Suggestions - Улправда
Does Mizuho’s New Coverage of Upstream Bio (UPB) Reframe the Stock’s Risk‑Reward Narrative? - Sahm
How Upstream Bio Inc. stock reacts to global recession fearsNew Guidance & Risk Controlled Swing Alerts - DonanımHaber
Will Upstream Bio Inc. stock beat EPS estimatesEarnings Growth Summary & Risk Adjusted Swing Trade Ideas - Улправда
Upstream Bio (NASDAQ:UPB) Stock Rating Upgraded by Mizuho - MarketBeat
Would You Still Hold Upstream Bio Stock If It Fell 30%? - Trefis
Is Upstream Bio Inc. stock overvalued by current metricsTrade Analysis Summary & Weekly Sector Rotation Insights - Улправда
How Upstream Bio Inc. stock reacts to inflationary pressures2025 Sector Review & Risk Managed Investment Strategies - DonanımHaber
Will Upstream Bio Inc. stock benefit from green energy trends2025 Top Gainers & Expert-Curated Trade Recommendations - Улправда
Chipmakers Recap: Can Upstream Bio Inc. stock weather global recessionJuly 2025 Levels & Low Risk Investment Opportunities - Улправда
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):